Evidence map›Paper›PMID 31022458›Full record

ReviewNeurobiology of disease2020

Positron emission tomography studies of organophosphate chemical threats and oxime countermeasures.

Charles M Thompson, John M Gerdes, Henry F VanBrocklin

Open access · hybridAbstract readReview
In one paragraph

Review in Neurobiology of disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. [The Journal of pharmacology and experimental therapeutics · 2024
    Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Charles M ThompsonDepartment of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT 59812, USA. Electronic address: charles.thompson@umontana.edu.
John M GerdesDepartment of Biomedical and Pharmaceutical Sciences, University of Montana, Missoula, MT 59812, USA.
Henry F VanBrocklinDepartment of Radiology and Biomedical Imaging, University of California, San Francisco 185 Berry St. Suite 350, San Francisco, CA 94107, USA.
University of Montana · USUniversity of California, San Francisco · US

Funding

Molecular Imaging of Chemical Threats and CountermeasuresU01NS092495 · NINDS · UNIVERSITY OF MONTANA · PI GERDES, JOHN M, THOMPSON, CHARLES MARK · 2015 to 2019
$3.9M
NINDS NIH HHS U01 NS092495
6 · The paper itself

Abstract

There is a unique in vivo interplay involving the mechanism of inactivation of acetylcholinesterase (AChE) by toxic organophosphorus (OP) compounds and the restoration of AChE activity by oxime antidotes. OP compounds form covalent adducts to this critical enzyme target and oximes are introduced to directly displace the OP from AChE. For the most part, the in vivo inactivation of AChE leading to neurotoxicity and antidote-based therapeutic reversal of this mechanism are well understood, however, these molecular-level events have not been evaluated by dynamic imaging in living systems at millimeter resolution. A deeper understanding of these critically, time-dependent mechanisms is needed to develop new countermeasures. To address this void and to help accelerate the development of new countermeasures, positron-emission tomography (PET) has been investigated as a unique opportunity to create platform technologies to directly examine the interdependent toxicokinetic/pharmacokinetic and toxicodynamic/pharmacodynamic features of OPs and oximes in real time within live animals. This review will cover two first-in-class PET tracers representing an OP and an oxime antidote, including their preparation, requisite pharmacologic investigations, mechanistic interpretations, biodistribution and imaging.

Indexed as

Nerve AgentsOrganophosphorus CompoundsRadiopharmaceuticalsAnimalsAntidotesCholinesterase ReactivatorsHumansOximesPositron-Emission TomographyAntidotesCholinesterase ReactivatorsNerve AgentsOrganophosphorus CompoundsOximesRadiopharmaceuticalsAcetylcholinesteraseAgingBiodistributionCarbon-11Fluorine-18ImagingInhibitionOrganophosphate/organophosphorusOximePharmacodynamics/toxicodynamicsPharmacokinetics/toxicokineticsPositron emission tomography (PET)Reactivation

Identifiers

PMID31022458
PMCPMC6810781
OpenAlexW2941431021

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.